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While the etiology of Parkinson’s disease remains largely elusive, there is accumulating evidence suggesting that mitochondrial
dysfunction occurs prior to the onset of symptoms in Parkinson’s disease. Mitochondria are remarkably primed to play a vital
role in neuronal cell survival since they are key regulators of energy metabolism (as ATP producers), of intracellular calcium
homeostasis, of NAD+/NADH ratio, and of endogenous reactive oxygen species production and programmed cell death. In this
paper, we focus on mitochondrial dysfunction-mediated alpha-synuclein aggregation. We highlight some of the findings that
provide proof of evidence for a mitochondrial metabolism control in Parkinson’s disease, namely, mitochondrial regulation of
microtubule-dependent cellular traffic and autophagic lysosomal pathway. The knowledge that microtubule alterationsmay lead to
autophagic deficiency and may compromise the cellular degradation mechanisms that culminate in the progressive accumulation
of aberrant protein aggregates shields new insights to the way we address Parkinson’s disease. In line with this knowledge, an
innovative window for new therapeutic strategies aimed to restore microtubule network may be unlocked.
1. Introduction
Parkinson’s disease (PD) was first associated with the loss of
the brown pigment neuromelanin from the substantia nigra.
Later, it was postulated that the progressive loss of dopamine-
producing cells in the substantia nigra pars compacta of the
ventral midbrain caused PD symptomatology. In addition,
PD is also associated with the presence of intracytoplasmatic
inclusions known as Lewy Bodies (LBs), which are com-
posed largely of alpha-synuclein (alpha-syn). The function
of alpha-syn is still unclear, but its involvement in PD
pathogenesis is further indicated by a subset of familial cases
of PD that carry either a missense mutation in snca (alpha-
syn) gene or have a duplication or triplication of alpha-syn
locus [1–4].
To date, mutations in at least 16 PD-genetic loci (PARK)
have been linked to the pathogenesis of PD [5]. The
discovery of these genes in which mutations cause early
or late-onset forms of PD has greatly accelerated research
progress. These include pink-1, dj-1, parkin, lrrk2, uchl-1,
omi/htra2, atp13a2, pla2g6, fbx07, and snca, as previ-
ously mentioned. OMI/HTRA2, PINK-1, DJ-1, LRRK2, and
Parkin are either mitochondrial proteins or are associated
with mitochondria and may be involved in pathways related
to oxidative stress and free radical damage. Pink-1 encodes
a putative serine/threonine kinase with a mitochondrial
targeting sequence [6], and DJ-1 is a redox sensor which is
involved in the response to oxidative stress [7]. Although
Parkin is a putative E3 ligase in the ubiquitin proteasome
system that localizes predominantly to the cytosol, it also
associates with the mitochondrial outer membrane [8].
Most recently mutations affecting the mitochondrial serine
protease OMI/HTRA2 have been linked to increased risk of
PD [9]. Mice entirely lacking expression of omi/htra2 due
to targeted deletion of its gene, Prss25, show a decrease in
a population of neurons in the striatum and have a parkin-
sonian phenotype that leads to death of the mice around
30 days after birth [10]. In addition, loss of Omi protease
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activity increases the susceptibility ofmitochondria to induce
the permeability transition pore [11]. LRRK2 is a kinase that
colocalizes with the mitochondrial outermembrane [12] and
may regulate the response to mitochondrial inhibitors [13].
PD etiopathogenesis includes genetic, epigenetic, and
environmental factors. However, in sporadic cases of PD,
in which ageing is the major risk factor, the initial event
that causes the pathology is not clear. Nevertheless, it is
known that several mechanisms are involved in the devel-
opment of PD pathogenesis such as mitochondrial dysfunc-
tion, oxidative damage, autophagic alterations, proteasome
impairment, microtubule network disruption, and protein
aggregation. Efforts have been made in order to discover
what triggers the pathogenesis of PD that culminates in
the death of a specific group of neurons, dopaminergic
neurons. Nowadays several studies highlight mitochondrial
dysfunction as the leading event. In this paper, we will
underscore mitochondrial-mediated mechanisms and their
involvement in PD pathogenesis.
2. Parkinson’s Disease:
AMitochondrial Disorder?
There is mounting evidence for mitochondria involvement
in neurodegenerative disorders, including PD. Mitochon-
dria play a fundamental role in energy metabolism; their
primary function is to provide energy (in the form of
ATP) for intracellular metabolic pathways. Mitochondrial
electron transport chain deficiencies are thought to underlie
defects in energymetabolism and have been implicated in the
neurodegenerative process. Moreover, brain cells are highly
dependent on the oxidative phosphorylation (OXPHOS)
machinery in mitochondria, which involves the respiratory
complexes [14].
The first evidence of mitochondrial dysfunction involve-
ment in the pathogenesis of PD emerged following the
observation that accidental exposure of drug abusers to
1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP), an
inhibitor of complex I (NADH/ubiquinone oxidoreductase)
of the mitochondrial electron transport chain, induced
parkinsonism [15]. Moreover, Parker and colleagues found a
significant reduction of complex I activity in platelet mito-
chondria, purified from patients with idiopathic PD [16].
Evidence for dysfunctional mitochondrial metabolism in PD
arises from studies performed in the substantia nigra of
postmortem PD brain showing a deficient complex I activity
[17, 18]. Additionally, a selective decrease in complex I
subunits was demonstrated in PD brain [19]. This was
corroborated by Keeney and coworkers that reported some
abnormalities in the assembly and oxidation of complex
I subunits in mitochondria from PD patients cortex [20].
Complex I deficiency has been also described in other
PD tissues, namely, in peripheral cell models such as,
platelets, lymphoblasts, muscle, and fibroblasts [21–26].
More recently, a specific complex I deficit was detected in
highly purified mitochondria from the frontal cortex of PD
patients [27]. To address mitochondrial involvement in the
pathogenesis of PD, King and Attardi, in 1989, succeeded in
repopulating human cells depleted frommtDNA, a Rho0 cell
line, with mitochondrial genes from donor cells [28]. Human
cell lines (SH-SY5Y neuroblastoma or NT2 teratocarcinoma
cells) depleted of mtDNA were fused with either control
or PD platelets that contain mtDNA, but no nuclear DNA.
Several authors showed that these cybrids harbour a complex
I defect [29–32] and have a decrease in ATP levels and loss
of mitochondrial membrane potential [29]. Further support
for mitochondrial involvement in PD comes from studies
using toxins [33–35] like rotenone, paraquat, andmaneb that
appear to reproduce some of the features of PD in animal
models. Although several of these toxins are mitochondrial,
they induce nigrostriatal lesions motor and postural deficits
by different mechanisms of action [36–44].
High levels of mtDNA deletions have been observed in
dopaminergic neurons from the substantia nigra of post-
mortem human brains from aged individuals and idiopathic
PD patients [45, 46]. mtDNA deletions in these neurons
were correlated with a decrease in cytochrome c oxidase
activity, one of the key enzymes of electron transport
chain. This suggests that accumulation of mtDNA deletions
in dopaminergic neurons from substantia nigra above a
certain threshold can cause mitochondrial defects associated
with PD. It is well established that mtDNA accumulates
mutations during the ageing process which correlates with
decline in mitochondrial function in late-onset PD. TFAM
is a phylogenetically conserved protein and is imported to
mitochondria which is essential for mtDNA maintenance
and directly regulates mtDNA copy number and is absolutely
required for transcription initiation at mtDNA promoters
[47–49]. The most compelling evidence regarding TFAM
involvement in PD was reported by Ekstrand and colleagues
showing that the conditional and selective inactivation
of both TFAM alleles in substantia nigra of transgenic
mice induced respiratory chain deficiency in dopaminergic
neurons leading to a Parkinsonism phenotype with adult
onset of slowly progressive impairment of motor function
accompanied by the formation of inclusions and neuronal
death [50]. Taking into consideration the above findings, it
was hypothesized that potentially functional polymorphic
TFAM variants could influence PD risk depending on hap-
logroup background. However, Alvarez and coworkers study
in 250 patients report no TFAM-mutations/polymorphisms
that could contribute to the risk for PD [51, 52]. Other
enzyme that regulates mtDNA replication and plays an
important role in mtDNA maintenance is the mtDNA
polymerase gamma 1 (POLG1). This enzyme is a nuclear-
encoded protein involved in the synthesis, replication, and
repair of mtDNA that is imported to mitochondria and
localizes in the inner mitochondrial membrane. POLG1
mutations might impair mtDNA replication, which leads
to gradual accumulation of multiple mtDNA deletions,
resulting in respiratory chain dysfunction [53]. Luoma and
colleagues have found that missense mutations of POLG1
cosegregate in patients with a phenotype that includes
progressive external ophthalmoplegia and parkinsonism [54,
55]. Moreover, POLG1 mutations have also been described
in case studies, in which parkinsonism was part of the
clinical spectrum [56]. Deletion of functional ndufs4, a gene
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encoding one of the subunits required for complete assembly
and function of complex I, led to abolished complex I activity
in midbrain mesencephalic cultures derived from ndufs4
knockoutmice [57]. However, this deletion did not affect the
survival of dopaminergic neurons in culture. Nonetheless,
studies performed in rats that expressed an enzyme called
“alternative NADH dehydrogenase” (Ndi1) in the substantia
nigra, showed a reduced toxic effect of MPTP and rotenone
[58, 59].
2.1. Oxidative Stress: ROS-Related Consequences. Mitochon-
drial OXPHOS is known to be the major source of ROS.
Cells in normal conditions are able to cope with exces-
sive ROS because they are endowed with robust endoge-
nous antioxidant systems. However, when ROS production
overwhelms the endogenous antioxidant systems, due to
mitochondrial dysfunction, this can potentially damage
various types of biomolecules, including proteins, lipids, and
nucleic acids. Markers of oxidative stress, such as products
of lipid peroxidation, protein oxidation, and oxidation of
mtDNA and cytoplasmic RNA, are increased in postmortem
samples of substantia nigra in PD brains as compared to
controls [60–64]. In PD patient’s postmortem substantia
nigra, there is evidence for decreased levels of reduced
glutathione and altered iron metabolism [65]. Furthermore,
proteomic studies revealed that several mitochondrial and
ROS scavenging proteins expressed in the substantia nigra of
PD patients had oxidative modifications supporting a role
of oxidative stress in PD [66]. It is strongly believed that
proximity of mtDNA to ROS generation site, the lack of
histones, and diminished capacity for DNA repair increase
mitochondrial vulnerability tomutations and oxidative stress
[67, 68]. It appears that substantia nigra is more vulnerable
to impairments of complex I activity than other brain regions
and peripheral blood cells, possibly due to increased levels
of iron and to dopamine metabolism [69]. The intracellular
auto-oxidation of dopamine generates H202and dopamine-
quinone species which will exert cytoxicity in dopaminergic
neuronal cells [70, 71].
Several papers showed an involvement of oxidative stress
in alpha-syn toxicity. Nitration and nitrosylation of proteins
and especially of alpha-syn and parkin in PD have been
documented [72–74]. Leong and coworkers demonstrated
that methionine oxidation of dopamine generates soluble
alpha-syn oligomers highlighting the potential role for
oxidative stress in modulating alpha-syn aggregation [75].
Interestingly, studies performed in SH-SY5Y cells overex-
pressing alpha-syn A53T mutant or wild type and in isolated
rat brain mitochondria showed that alpha-syn localizes at
the mitochondrial membrane, and this interaction of alpha-
syn with mitochondria causes oxidative modification of
mitochondrial components [76].
The involvement of oxidative stress in PD is also
corroborated by the fact that two of the PD-related genes,
dj-1 and pink-1, have important roles in maintaining the
balance between oxidative stress and antioxidant defenses.
DJ-1 functions as a redox-sensitive chaperone as well as a
sensor for oxidative stress and apparently protects neurons
against oxidative stress and cell death. Mutations in this
gene are the cause of autosomal recessive early-onset PD
[77]. Hayashi and colleagues suggested that DJ-1 is an
integral mitochondrial protein that directly plays a role
in maintenance of mitochondrial complex I activity [78].
PINK-1 is a serine/threonine protein kinase that localizes
to mitochondria. It is thought to protect cells from stress-
induced mitochondrial dysfunction. Mutations in this gene
cause one form of autosomal recessive early-onset Parkinson
disease [6].
Taken together these findings suggest a pivotal role for
mitochondrial-mediated oxidative stress in PD pathogenesis.
2.2. Mitochondrial Metabolism: NAD+/NADH Ratio. Sev-
eral studies suggest that changes in energy metabolism
in the brain are not merely a consequence of neuronal
loss but rather a contributory factor to the progression
and development of the disease [79–83]. The decrease
in mitochondrial bioenergetics capacity and altered redox
status is linked through various mechanisms includ-
ing interconvertible reducing equivalent pool: NAD+ and
reduced β-nicotinamide adenine dinucleotide (NADH) [84].
NAD+ and NADH are major factors for numerous energy
metabolism-associated redox reactions and mitochondrial
functions but also calcium homeostasis, ageing, and cell
death [85]. Additionally, NAD+/NADH ratio is a powerful
regulator of glycolysis, TCA cycle, and oxidative phospho-
rylation. Our group recently observed that NAD+/NADH
ratio is significantly increased in PD cybrids when compared
with CT cybrids (Esteves et al., submitted). By using an
oxygen electrode, we observed that although whole cell basal
oxygen consumption was comparable between the PD and
CT cybrids, the proton leak was increased and maximum
respiratory capacity was decreased in the PD cybrids [86].
Multiple families of enzymes catalyze various biochem-
ical reactions by consuming NAD+. Among these are the
recent identified sirtuins (SIRTs) that have a catalytic domain
characterized by its requirement for NAD+ as a cofactor.
SIRTs are a family of deacetylase enzymes that are able to
remove the acetyl group from ε-amine of lysine and have
been found in a wide variety of subcellular locations. So
far, in humans there are seven identified SIRTs (SIRT1 to
SIRT7) that play a role in a wide variety of important bio-
logical processes, including transcriptional silencing, DNA
recombination and repair, apoptosis, axonal protection, fat
mobilization, and ageing [87]. The deacetylase and ADP
ribosylase activity of SIRTs suggests that they could act as
metabolic or oxidative sensors, regulating cellular machinery
according to the information they receive. Resveratrol, an
activator of SIRT1 [88], protected SH-SY5Y cells against
dopamine-induced cytotoxicity by reducing intracellular
oxidative stress [89]. Additionally, it was shown to exert a
neuroprotective effect on 6-OHDA rat model of PD [90]
and to significantly protect mice fromMPTP-induced motor
coordination impairment, hydroxyl radical overloading, and
neuronal loss [91]. On the other hand, a work from 2009
showed that SIRT1 overexpression did not exert any neuro-
protective effect against neuronal damage induced by MPTP
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in mice [92]. A dramatic reduction in the expression of
SIRT1 occurred when an acute stress was induced by addition
of several neurotoxins (MPP+, rotenone, KA, or 3NPA) to
the culture medium. However, in human samples of PD
and dementia with LBs, there were no changes in SIRT1
expression [93]. So far, no work has been published regarding
SIRT1 involvement in alpha-syn oligomers clearance in
PD. In an MPTP-treated primate model of PD, caloric
restriction, wich upregulates SIRT1, prevented the function
of locomotor function and preserved striatal dopamine [94].
SIRT1 is known to deacetylate approximately a dozen of
known substrates, such as peroxisome proliferator-activated
receptor gamma coactivator-1 alpha (PGC1α). PGC1α is
of major importance for PD etiopathogenesis because it
plays a central role in the regulation of cellular energy
metabolism and stimulates mitochondrial biogenesis. Work
from our group demonstrated that PD cybrids with inher-
ent mitochondrial dysfunction have a decrease in SIRT1
activity that was correlated with a decrease in PGC1α
levels indicating that mitochondrial biogenesis is affected
in our PD model [86]. However, more studies need to be
performed in order to substantiate this data. The role of
SIRT2 in neurodegenerative disorders is less established.
Nevertheless, North and coworkers provided data revealing
that SIRT2 is involved in cell cycle regulation via the
deacetylation of α-tubulin [95]. More recently, Outeiro
and coworkers reported an intriguing connection between
SIRT2 and PD that suggested that inhibition of the human
SIRT2 rescues cells from alpha-syn-mediated toxicity [96].
The exact mechanism whereby SIRT2 inhibition affects
alpha-syn aggregation remains uncertain. One proposed
mechanism is through alpha-syn interaction with alpha-
tubulin [97–99]. Moreover, it was shown that PD cybrids
have an increased free/polymerized tubulin ratio indicating
that microtubule destabilization may mediate alpha-syn
oligomers accumulation [98]. Apha-tubulin acetylation is
associated with microtubule stabilization, so one possibility
is that an increase in SIRT2 activation due to increase in
NAD+ levels increases alpha-tubulin deacetylation leading to
microtubules network disruption which potentiates alpha-
syn oligomerization (Esteves et al., submitted). So far, little
is known about the remaining SIRTs involvement in PD.
Overall, SIRTs targeting may be therapeutically beneficial in
PD pathogenesis by manipulating the pathways responsible
for PD neurodegeneration not only regarding alpha-syn
oligomerization but also mitochondrial biogenesis. However,
despite exciting data, the feasibility of developing SIRTs-
based therapy for PD and other neurodegenerative diseases
needs to be demonstrated in animal models, and finally in
human trials.
2.3. Calcium Homeostasis Deregulation. Disturbances in cal-
cium homeostasis can affect neuronal functionality since
calcium is one of the most important elements in cellular
signaling. An increase in cytosolic calcium concentration can
arise from two sources: the major intracellular calcium store
which is the endoplasmic reticulum and the extracellular
space. Moreover, mitochondrial function is based on the
ability to uptake calcium and to accumulate it in the matrix,
being this process dependent on the mitochondrial mem-
brane potential. The primary role of mitochondrial calcium
is the stimulation of OXPHOS [100]; thus, any perturbation
in mitochondrial or cytosolic calcium results in profound
alteration of cellular function. Rotenone was shown to
increase the susceptibility of cells to calcium overload with
subsequent cell death in SH-SY5Y neuroblastoma cells [101].
Sheehan and coworkers showed that PD cybrids sequestered
less calcium in their mitochondria than CT cybrids, due to
their decreased mitochondrial function [102]. Subsequently,
our work showed that PD cybrids have a significantly
higher concentration of cytosolic calcium as compared to CT
cybrids and in addition show less capacity in mitochondrial
calcium buffering, indicating that mitochondrial normal
function is impaired [103].
In addition, an increased activity of calcium-stimulated
phospholipase A2 in the putamen is reported to be due to
either decreased dopaminergic striatal input or degenerative
processes in dopamine nerve terminals [104]. Dopaminergic
neurons from substantia nigra express calcium buffering
proteins which effectively sequester calcium without using
ATP. Expression of the calcium buffering protein, calbindin,
reduces vulnerability to mitochondrial toxins [105] and
seems to confer resistance to MPTP [106]. Interestingly,
dopaminergic neurons that do not express the Ca2+-
buffering protein, calbindin-D28k, are selectively lost during
PD progression [107]. In addition, dopaminergic neurons
that express relatively high levels of another calcium-
buffering protein, calretinin, appear to be resistant to
degeneration in PD [108].
So far, it has been demonstrated that alpha-syn regulates
calcium entry pathways and, consequently, that abnormal
alpha-syn levels may promote neuronal damage through
deregulation of calcium homeostasis [109].
3. Mitochondrial Metabolic Control of
Cellular Traffic: Microtubules Involvement
Cytoskeletal injury is likely to be responsible for altered rear-
rangement and movement of organelles, being a common
feature of several neurodegenerative diseases including PD.
Microtubules are highly dynamic polar structures that play
critical roles in diverse cellular functions. These include cell
motility and division, organelle transport, cell morphology,
and organization. Intracellular transport of protein and
organelle cargo is one of microtubules’ most important
function, and is an essential requirement for all mammalian
cells. In addition, microtubule-mediated transport is cru-
cial to maintain the function and structure of neurons
[110]. Microtubules dynamic instability requires an input
of energy to undergo polymerization and depolymerization
cycles. This dynamic process is extremely regulated and is
influenced by many factors, where the concentration of free
tubulin is the driving force [111].
Several lines of evidence suggested that microtubules
disruption may be involved in PD. In fact, tubulin was shown
to colocalize with alpha-syn in LBs. Also, tubulin folding is
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dependent on ATP and GTP hydrolysis, and mitochondrial
impairment with subsequent energy failure is one of PD
hallmarks [112, 113]. Toxins that affect ATP production may
affect the tubulin polymerization/depolymerization process
leading to an increase in free tubulin. In fact, MPP+,
a known complex I inhibitor that induces PD-like symptoms,
depolymerizes microtubules in PC12 cells [114, 115]. Later,
Cappelletti and coworkers provided the first evidence that
microtubules instability is specifically affected by MPP+
[116]. Moreover, rotenone, another complex I inhibitor, was
also shown to potentiate microtubules depolymerisation in
vivo and in vitro [117] by binding to the colchicine site
on tubulin heterodimers [118]. Ren and Feng found that
microtubule depolymerization induced by rotenone caused
vesicle accumulation in the soma and killed serotonergic
neurons through a mechanism dependent on serotonin
metabolism in the cytosol [119].
Microtubule depolymerization induces disruption in
axonal transport, which leads to an accumulation of dam-
aged organelles, aggregated/misfolded proteins, and vesicles.
What happens in dopaminergic neurons is that dopamine
leakage from the vesicles to the cytosol promotes an increase
in oxidative stress induced by dopamine oxidation which cul-
minates in cell death [120]. Treatment of cotransfected cells
or primary mesencephalic neurons with colchicine, vinblas-
tine, or nocodazole reversed alpha-syn-mediated inhibition
of DAT activity providing insights for alpha-syn regulation
of DAT activity, namely, by tethering the transporter to
the microtubular network [121]. Furthermore, treating cells
with nocodazole, a microtubule-disrupting agent, resulted
in an increase in the number of small aggregates parti-
cles. Indeed, perturbation of microtubule system due to
inhibition of microtubule assembly or due to deletion of
genes involved in microtubule biogenesis stimulates alpha-
syn aggregation and toxicity [122]. Also Webb and cowork-
ers found that microtubule disruption with nocodazole
inhibits autophagosome-lysosome fusion, what can decrease
the degradation of alpha-syn oligomers [123]. Our group
demonstrated that taxol, a microtubule stabilizer, was able
to reduce alpha-syn oligomers accumulation in PD cybrids
[98]. Intriguingly, the process of alpha-syn fibril formation
was shown to be stimulated by tubulin and two other
microtubule-associated proteins [124–126]. This means that
when microtubule network is disrupted, the amount of free
tubulin increases triggering alpha-syn fibrillization. Indeed
alpha-tubulin directly interacts with alpha-syn [127]. On
the other hand, Alim and collaborators found that alpha-
syn is a functional microtubule-associated protein, and
mutant forms of alpha-syn lose this potential [97]. Alpha-syn
overexpression induces not only microtubule disruption but
also impairs microtubule-dependent trafficking and induces
neuritic degeneration in SH-SY5Y cells [128]. Moreover,
Saha and colleagues found that the movement of alpha-
syn mutant forms associated with PD through axons of
cultured neurons has reduced transport rates. In addition,
phosphorylation of alpha-syn in serine-129 also reduces its
axonal transport [129].
Mitochondria use cytoskeletal proteins as tracks for their
directional movement. Interaction of mitochondria with
microtubules and their movement along microtubule tracks
depends on MAPs [130]. The cytoskeletal system regulates
not only mitochondrial movement but also their mor-
phology and function. Therefore, damage to microtubules
interferes with mitochondria movement through axons. On
the other hand, mitochondria damage perturbs transport
of mitochondria through axons, increasing their retrograde
movement. These changes in mitochondria dynamics lead
to a decrease of mitochondria numbers in axons and
mitochondria accumulation in cell bodies [131, 132]. Studies
from 2002 revealed that depletion of mitochondria num-
bers and function in axons occurs in neurodegenerative
disorders [133, 134]. Since mitochondria are ATP suppliers
and microtubules need ATP to accomplish their function,
damage to mitochondria will have a profound effect on
axonal transport and as a consequence axonal maintenance
and function [135]. Normal mitochondria are expected
to generate sufficient amounts of ATP but also to divide
[136]. Indeed, mitochondrial biogenesis occurs by fission
of pre-existing mitochondria. Fission allows the dilution
of damaged macromolecules and also prevents excessive
mitochondria enlargement. In fact, enlarged mitochondria
are less likely to be degraded bymitophagy, which potentiates
their progressive failure [137]. Initial enlargement may occur
because of oxidative damage to proteins responsible for
mitochondrial fission or mutations in the corresponding
nuclear genes. Moreover, mitochondrial turnover may also
decrease due to decreased lysosomal capacity associated with
lipofuscin overload. It is also called “ageing pigment” and
has been considered a reliable biomarker for the age of neu-
rons. Lipofuscin is an intralysosomal, polymeric substance,
primarily composed of cross-linked protein residues and
formed due to iron-catalyzed oxidative processes. Because
it is undegradable and cannot be removed via exocytosis,
lipofuscin accumulation is inevitable during ageing [138,
139]. The accumulation of lipofuscin within postmitotic cells
is a recognized hallmark of ageing occurring with a rate
related to longevity.
An increasing body of data emphasizes the crucial
role of mitochondrial dynamics in mitochondria function.
Mitochondria are not a static and autonomous organelle
but, instead, a highly dynamic one. This organelle under-
goes continual cycles of fusion (the combination of two
mitochondria into a single organelle) and fission (the
separation of long, tubular mitochondrion into two or more
smaller parts) [140, 141]. These dynamic processes reg-
ulate mitochondrial function by enabling mitochondrial
recruitment to critical subcellular compartments, content
exchange between mitochondria, mitochondrial shape con-
trol, mitochondrial communication with the cytosol, and
mitochondrial quality control. In fact, this highly dynamic
balance between mitochondrial fission and fusion controls
mitochondrial morphology, length, size, and number and
also regulates mitochondrial function and distribution.
Increasing evidence suggests that abnormal mitochondrial
dynamics is involved in mitochondrial dysfunction which
may mediate neuronal death in PD models. Interestingly,
MPP+ and rotenone were shown to induce mitochondrial
fragmentation dependent on the fission protein GTPase
6 Parkinson’s Disease
Dynamin-related protein 1 (Drp1) [142–144]. Similarly, 6-
OHDA-induced mitochondrial fragmentation in SH-SY5Y
cells suggests that excessive mitochondrial fission might
be mediating neurotoxicity induced by complex I inhi-
bition [145]. In human fibroblasts, acute exposure to
high-dose rotenone resulted in decreased mitochondrial
membrane potential that caused mitochondrial fragmented
morphology [146]. Also chronic exposure to rotenone was
reported to reduce mitochondrial movement in differen-
tiated dopaminergic SH-SY5Y cells [147]. These results
suggest that PD toxins hamper fission/fusion machinery.
Work obtained with two PD-related genes also highlighted
microtubules involvement in PD as well as mitochondria
dynamics impairment. For instance, parkin was shown to
strongly bind to microtubules and to ubiquinate tubulin
[120]. In addition, PINK-1 was found to have a role in the
trafficking of mitochondria along microtubules suggesting
that loss of PINK-1 function besides altering mitochondrial
morphology and dynamics can also alter microtubule func-
tion [148]. It was also suggested that the PINK-1/Parkin
pathway promotes mitochondrial fission and/or inhibits
fusion by negatively regulating fusion proteins function,
such as Mitofusin-1 and -2 (Mfn1 and Mfn2) and Optic
atrophy 1 (Opa1), and/or positively regulating Drp1 [149].
Moreover, the loss of mitochondrial integrity in PINK-1 and
parkin mutants can be due to reduced mitochondrial fission
[150]. In Drosophila, PINK-1 and parkinmutant phenotypes
were markedly suppressed by overexpression of Drp1 or
downregulation of Opa1 indicating that the PINK-1/Parkin
pathway regulates mitochondrial remodeling process by
promoting mitochondrial fission [151]. Additionally, PINK-
1 deficiency is also linked to mitochondrial pathology in
human cells and Drosophila, which can be rescued by
Exner et al. [152]. Lutz and colleagues demonstrated that
an acute downregulation of parkin in human SH-SY5Y cells
severely affects mitochondrial morphology and function,
a phenotype comparable with that induced by PINK-1
deficiency. Furthermore, they showed that loss of parkin or
PINK-1 function increases Drp1-dependent mitochondrial
fragmentation [153]. Narendra and colleagues demonstrated
that dysfunctional mitochondria, with a low membrane
potential, recruit parkin to the mitochondria and induce
the mitochondria to undergo fusion and mitophagy [154].
Furthermore, the loss of PINK-1 function elicited oxidative
stress and mitochondrial turnover that was coordinated by
the autophagic and fission/fusion machineries [155, 156].
Overall, mitochondrial-mediated microtubule disrup-
tion leads to a rapid accumulation of protein aggregates
and/or damaged organelles such as mitochondria contribut-
ing to neurodegeneration as seen in PD.
4. Protein Aggregation: Alpha-Synuclein
Oligomerization
When misfolded proteins cannot be refolded or degraded
(by the proteasome or by the lysosome), the cell activates
an alternative way of defence, sequestering abnormal and/or
toxic proteins into aggregates. There is convincing data
pointing to protein aggregation role in both familial and
sporadic PD pathogenic process. Indeed, the presence of
spherical protein inclusions is found in the cytoplasm of
surviving nigral neurons, named LBs. It is thought that
fibrillar alpha-syn is the building block of LBs. Indeed, alpha-
syn is also the most sensitive marker for LBs, implying
that it is necessary for LBs formation [157]. Nevertheless,
LBs contain many proteins other than alpha-syn, including
neurofilaments and other cytoskeletal proteins, suggesting
that they might be important in aggresome formation.
Alpha-syn is a small, highly charged 140-amino acid residue
protein predominantly expressed in CNS, whose function
is still poorly understood. However, several functions have
been pointed out. It is thought that alpha-syn plays a role
in the regulation of dopamine biosynthesis via activation of
protein phosphatase 2A that reduces tyrosine hydroxylase
phosphorylation, the rate-limiting enzyme in dopamine
production [158, 159], and reducing the amount of available
active mitogen-activated protein kinases [160] and phos-
pholipase D [161]. Furthermore, several studies suggest that
alpha-syn is involved in modulating synaptic transmission,
the density of synaptic vesicles, and neuronal plasticity [162–
165]. In addition, alpha-syn can act as molecular chaperone
preventing aggregation of other proteins in vitro. In fact,
alpha-syn can activate Hsp70, and more interestingly its
structure is very similar to heat shock proteins [166, 167].
It also provides a supportive role in the folding/refolding of
SNARE proteins critical for neurotransmitter release, vesicle
recycling, and synaptic integrity [168]. Interestingly, alpha-
syn knockout mouse showed no signs of neurodegeneration
suggesting that alpha-syn is not required for neuronal
development [165, 169]. SNCA gene mutations are very rare
(three missense point mutations A30P, A53T, and E46K)
however, they have helped to elucidate molecular mecha-
nism of intracellular accumulation of alpha-syn. Transgenic
mice expressing human wild-type alpha-syn gene develop
several of clinical and pathological features of PD, such as
accumulation of LBs, the loss of dopaminergic terminals in
the basal ganglia, and associated motor impairments [170].
Overexpression of alpha-syn in substantia nigra results in
loss of dopaminergic neurons, phosphorylation of alpha-
syn at Ser129, and activation of caspase-9 [171]. Moreover,
A53T and A30P alpha-syn transgenic mice develop neuronal
mitochondrial degeneration and cell death [172]. Interest-
ingly, A30P and A53T mutant alpha-syn are known to self-
associate more rapidly than the wild-type forms facilitating
aggregation into fibrils [173–176]. However, transgenic mice
with A30P alpha-syn mutation do not exhibit alpha-syn
inclusions [177]. In contrast, A53T alpha-syn transgenic
mice develop neuronal synucleinopathy [178].
Alpha-syn can interact with many proteins, like calpain
1 that can cleave alpha-syn in the C-terminal region further
enhancing its fibrillization process [179]. Likewise, alpha-
tubulin induces alpha-syn fibrillization in yeast, rat brain,
and human brain [122, 125]. Moreover, work from our lab
demonstrated that in PD cybrids with a complex I defect
and ATP depletion both calpain 1 over-activation and free
alpha-tubulin increase trigger alpha-syn oligomerization [98,
103]. Numerous studies now support the hypothesis that
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alpha-syn oligomerization is the key step driving neuronal
damage in PD. Indeed, the idea that oligomers, rather than
the fibrils, are the pathogenic aggregate species that are
responsible for neuronal cell death in PD is emerging. In
fact, based on several observations, it has been suggested
that LB formation does not cause but, instead, protects
against neurodegeneration [180, 181]. Interestingly, neu-
ropathological analysis of PD patients’ brains has shown that
neurons containing LBs seem healthier than neighbouring
neurons [182, 183]. Although the mechanism underlying the
cytotoxicity of the oligomers is not clear [184, 185], earlier
studies showed that alpha-syn protofibrils disrupt synthetic
vesicles in vitro [186, 187] causing imbalance of cellular
ions and, thus, cell death. Several alpha-syn posttranslational
modifications lead to the formation of stable oligomers.
These include nitration, oxidation, phosphorylation, and
interaction with iron. Oxidative modification of alpha-syn
via dopamine adducts may facilitate aggregation [175]. Sim-
ilarly, recent data demonstrated that stable overexpression of
alpha-syn in SH-SY5Y cells or exposure of cells to dopamine
facilitated alpha-syn oligomerization [188]. Dopamine was
shown to modulate differently the stability of protofibrils
and fibrils composed of wild-type or mutant forms of alpha-
syn [189]. Wakamatsu and coworkers showed that truncated
human alpha-syn is deleterious to the development and
survival of nigral dopaminergic neurons [190]. Likewise, a
work from 2007 demonstrated that aggregated alpha-syn
mediates dopaminergic neurons toxicity in vivo [191].
Other mechanisms showed that alpha-syn aggregation
might be closely related to oxidative reactions which may
play a critical role in PD neurodegeneration [192]. For
instance, abnormalities in copper and H2O2 homeostasis
were shown to play critical roles in the metal-catalyzed
oxidative oligomerization of alpha-syn [193]. Additionally,
by using antibodies to specific nitrated tyrosine residues
in alpha-syn, extensive and widespread accumulation of
nitrated alpha-syn protein inclusions was demonstrated in
protein inclusions of PD brains [72]. Subsequently, it was
found that in HEK 293 cells stably transfected with wild-
type and mutant alpha-syn, nitrative and oxidative insults
induced the formation of alpha-syn aggregates [194]. Our
results in PD cybrids indicate thatmitochondrial-driven ROS
production induces alpha-syn oxidation and oligomeriza-
tion. Alpha-syn aggregation was significantly decreased upon
antioxidant treatment (CoenzymeQ or GSH) [30].
Other important covalent promoter of aggregation is
phosphorylation. Alpha-syn carries a number of potential
sites for phosphorylation. Indeed, Ser129 phosphorylation
of alpha-syn strongly modulates interactions between alpha-
syn and synphilin-1 and the formation of inclusions. The
levels of soluble alpha-syn oligomeric species are increased
by phosphorylation at Ser129 [195]. It was shown that alpha-
syn is extensively phosphorylated in aggregates from synucle-
inopathies patients [196]. In addition, polyunsaturated fatty
acids were reported to promote oligomerization, suggesting
that alpha-syn may aggregate via interaction with cell
membranes [197]. One proposed mechanism for oligomers
toxicity, as previously mentioned, is the formation of pores
by ring-like intermediates. Moreover, iron was shown to
specifically induce alpha-syn aggregation suggesting its role
in aggregate formation [198].
Evidences suggest that mitochondrial dysfunction could
induce alpha-syn misfolding. In fact, treatment with
rotenone resulted in an increase of detergent-resistant alpha-
syn aggregates in COS-7 cells expressing wild-type alpha-syn
[199]. Moreover, mutant and wild-type alpha-syn interacts
with mitochondrial cytochrome c oxidase, a key enzyme of
the mitochondrial respiratory system [200]. Li and cowork-
ers demonstrated that a portion of alpha-syn is present in
the membrane of mitochondria in normal dopaminergic
neurons [201]. Under overexpression conditions, alpha-syn
may translocate to the mitochondria and cause enhanced
toxicity in response to subtoxic concentrations of mitochon-
drial toxins [202]. Using SHSY cells overexpressing alpha-
syn A53T mutant or wild-type, as well as isolated rat brain
mitochondria, it was shown that alpha-syn localizes at the
mitochondrial membrane causing oxidative stress [76].More
recently, Devi and colleagues showed that mitochondria of
PD-vulnerable substantia nigra and striatum had significant
accumulation of alpha-syn and decreased complex I activity
[203]. Another interesting study demonstrated that during
the ageing process in yeast, functional mitochondria are
required for alpha-syn toxicity [204]. Furthermore, our work
provided data showing that PD cybrids harbouring inherent
mitochondrial impairment developed alpha-syn oligomers
accumulation. Alpha-syn oligomerization in our studies was
triggered by several different pathways all dependent on
mitochondria malfunction (reviewed by [205]).
Although more studies need to be performed in order
to elucidate alpha-syn function, it is quite undeniable that
its oligomerization seems to be the key step that drives both
pathology and cellular damage in PD.
5. IntracellularMechanisms of Degradation
5.1. Calpain-Mediated Proteolysis. Sustained mitochondrial
dysfunction in PD can release calcium, contributing to
aberrant calcium homeostasis in the cytosol leading to
activation of calpains. Indeed, mtDNA-depleted cells exhibit
an increase in calpain activation [206]. Calpains are calcium-
activated neuronal proteases that belong to a highly con-
served family of cysteine proteases, thus, they are widely
expressed in the CNS and are preferentially involved in
the degradation of short-lived proteins [207]. Its structure
consists of a cysteine-proteinase domain combined with a
calmodulin-like Ca2+-binding domain. In fact, the activi-
ties of the representative classical, ubiquitous mammalian
calpains, μ-calpain (calpain 1), and m-calpain (calpain
2) are regulated by Ca2+ concentration. They exist as a
proenzyme heterodimer (80 kDa and 29 kDa) in resting cells
but are activated by calcium through autolytic processing (to
produce a heterodimer of 78 kDa and 18 kDa). Furthermore,
in vitro studies showed that calpain 1 and 2 differ in the
calcium concentration required to become activated; calpain
1 requires a calcium concentration in the μmolar range, and
calpain 2 requires mmolar range [208]. It is widely known
that calpastatin, a ubiquitously expressed 110 kDa protein,
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is the sole endogenous inhibitor of calpains [209, 210].
Overall, calpains are intracellular nonlysosomal calcium-
regulated cysteine proteases that mediate regulatory cleav-
ages of specific substrates and are involved in a number of
processes during differentiation, life, and death of the cell.
These proteases cleave diverse proteins species, including
receptors, ion channels, cytoskeletal components, proteases,
oncogenic proteins, and cell signalling proteins. Although
calpain activation was initially implicated in the necrotic
process, several studies have indicated that these proteases
play a prominent role in apoptotic processes. In fact, calpains
are able to be activated via caspase-mediated cleavage of
calpastatin during initiation of apoptotic execution [211].
Active caspase-3 can cleave calpastatin, thereby promoting
uncontrolled calpain activation. Although calpains may
enhance caspase activity, they can also function to block
the activation of caspases. For example, calpains can cleave
caspase-9 rendering it incapable of activating caspase-3
and preventing the subsequent apoptotic cascade [212].
Moreover, procaspase-3 is a calpain substrate. In PC12 cells,
MPP+ induced calpain activation and AIF release which was
prevented by calpain inhibitors [213].
Cdk5 belongs to a group of serine/threonine kinases best
characterized for their role in cell cycle progression. This
kinase was shown to have a role in the pathogenesis of PD.
Cdk5 has been colocalized with LBs in PD patients’ brains.
Conversion of the cdk5 activator p35 to the more stable p25
form may lead to increased cdk5 activity. Consistent with
this possibility, an increase in p25 levels was shown after
MPTP treatment. Several reports suggest that the p35-to-
p25 conversion is mediated through calpain activation [214–
216]. Increased expression of calpain in the mesencephalon
of PD patients and primate PD models has been demon-
strated, suggesting a calpain involvement in PD pathogenesis
[217]. Additionally, enhanced calpain expression and activity
is observed in the substantia nigra and locus coeruleus of PD
patients. Increased calpain expression and cell death in spinal
cord in C57BL/6N mice were also reported following MPTP
treatment [218]. The presence of calpains inmorphologically
abnormal dopaminergic fibers as well as in LBs further
supports calpains involvement in PD. Most interestingly,
inhibition of calpain blocks neuronal degeneration and
restores behavioural function in experimental models of PD
[219]. Likewise, the inhibition of mitochondrial complex I
by MPP+ and rotenone activated calpain and seems to
constitute an early event in the neurodegenerative process
prior to caspase-3 activation [220, 221]. Moreover, rotenone-
induced degeneration of spinal cord motor-neuron in male
Lewis rats progressed with upregulation of calpain and
caspase-3 [222].
It is now well accepted that alpha-syn oligomerization is
pivotal in progression of PD pathology and cellular damage.
Subsequently, it has been described in other diseases that
involve protein aggregation, the protective effect of calpain
inhibition. Haacke and coworkers showed that coexpression
of the highly specific cellular calpain inhibitor calpastatin
abrogated fragmentation and the formation of inclusions
in cells expressing pathological ataxin-3 suggesting a critical
role of calpain in the pathogenesis of Spinocerebellar ataxia
type 3 [223]. Moreover, Gon˜i-Oliver and colleagues provided
data that established the first direct evidence that calpain
promotes GSK-3 truncation in a way that has implications in
signal transduction, and probably in pathological disorders
such as AD [224]. In 2003, it was shown that parkin acceler-
ates the degradation of alpha-syn via the activation of calpain
leading to the prevention of alpha-syn-induced cell death
[225]. Also in 2003, it was demonstrated that alpha-syn was a
substrate of calpain 1 [179]. Latterly, the same group showed
data revealing that calpain-mediated cleavage near and
within the middle region of soluble alpha-syn with/without
tyrosine nitration and oxidation generates fragments that are
unable to self-fibrillized [226]. As opposed, Dufty and col-
leagues in 2007 showed that cleavage of alpha-syn by calpain
occurs in PD brain and calpain-cleaved fragments of alpha-
syn colocalized with activated calpain [227]. These results
suggest that calpain may link alpha-syn to its disease-linked
oligomerization, aggregation, and subsequent formation of
LBs. Our group showed that PD cybrids have increased
cytosolic calcium levels correlated with an increase in calpain
activation and expression which subsequently potentiates the
formation of toxic alpha-syn oligomers. In addition, our
results showed that calpains inhibition decreased the toxic
alpha-syn oligomers and increased the nontoxic insoluble
alpha-syn aggregates, preventing caspase-3 activation [103].
Demarchi and collaborators showed that calpain mod-
ulates macroautophagy in mammalian cells [228]. Indeed,
in calpain-deficient cells, autophagy is impaired, thus con-
tributing to the apoptotic switch. Recent data showed that
in AD the lysosomal autophagic system may not degrade
tau in the normal adult rat brain. However, inhibition
of autophagy may induce tau proteolysis through calpain
activation [229]. So far, no data was shown confirming the
correlation between autophagy and calpains in PD.
Overall, a role for calpains-mediated proteolysis is
strongly postulated in the pathogenesis of PD. More studies
need to be performed to address if calpains inhibition offer a
potential therapeutic target in the neurodegenerative process
of PD.
5.2. Autophagy: A Quality Control System. Age causes a
progressive accumulation of wornout organelles and sub-
cellular structures that reduces the cellular and molecular
efficiency of various biological processes that are required for
maintaining homeostasis and survival. This accumulation
of extracellular/intracellular damaged proteins has been
frequently used as a biomarker of ageing [230]. Moreover, it
seems to reflect an unbalance between the capability/activity
of the quality control systems and the amount of altered
proteins in the cells. Autophagy is ubiquitous in eukary-
otic cells and is the major mechanism involved in the
clearance of oxidatively or otherwise damaged/worn-out
macromolecules and organelles, controlling thus cell death.
Autophagy is a process traditionally regarded as a cellular
response to stress typically related to nutrient deprivation,
toxin exposure, infection, or oxidative stress. In contrast to
the ubiquitin-proteasome pathway which degrades mostly
short-lived proteins, autophagy is primarily involved in
breaking down proteins with long half-lives and damaged
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organelles [231]. Moreover, is a highly organized and prob-
ably quite specific intralysosomal degradation pathway reg-
ulated by a large family of genes, the ATG family [232, 233].
Over 30 atg genes have been identified in yeast and at least 11
have orthologs in humans. For instance, atg6 is also known
as beclin and atg8 is commonly called LC3 in mammals
[234, 235]. There are three main types of autophagy in
mammalian cells: macroautophagy, microautophagy, and
chaperone-mediated autophagy (CMA) [236]. The differ-
ences among the various autophagic mechanisms depend
of the type of cargo, route, and mechanism for its delivery
to lysosomes. Macroautophagy involves any type of cellular
material, including large organelles, such as mitochondria,
being sequestered within a double-membrane-bounded vac-
uole called autophagosome. Autophagosomes receive acid
hydrolases by fusion with late endosomes or lysosomes.
Subsequently, the degradation of its content progresses and
matures to a secondary lysosome or residual body depending
on whether degradation is complete or partial, respectively
[237–239]. Microautophagy involves macromolecules and
small organelles that enter lysosomes through invagination
of its membrane [240, 241]. CMA is a mechanism for
selective digestion of a particular group of soluble cytosolic
proteins with a KFERQmotif [233, 242]. Once this sequence
is recognized, these proteins are directly translocated to the
lysosomal membrane.
Alterations in the autophagic machinery have been
implicated in the pathogenesis of PD. Indeed, an increased
number of autophagic vacuoles and related structures of
autophagy have been found in PD patients [243]. In
addition, autophagic vacuoles are also described within mes-
encephalic dopaminergic neurons in several experimental
models of PD [244, 245]. LC3-II and Beclin-1 expressions
were significantly increased in brains from humans with
Dementia with LBs and in transgenic mice overexpressing
A53T alpha-syn, as compared with respective controls [246].
However, the lysosome-associated membrane protein 1
(LAMP1), cathepsin D (CatD), and Heat Shock Protein 73
(HSP73) immunoreactivity were significantly decreased
within PD nigral neurons when compared to age-matched
controls [247]. There is controversy over whether this
increase in autophagicmarkers is protective or instead causes
neuronal death. It has been suggested that this increase is
responsible for neuronal death. However, enhanced degra-
dation of deleterious aggregates or disrupted organelles can
be protective [248].
Autophagy is indeed an important process in a variety
of human diseases caused by toxic, aggregate-prone, intracy-
tosolic proteins which became inaccessible to the proteasome
when they form oligomers [249, 250]. Depending on its
conformational state and cellular conditions, alpha-syn can
be degraded by autophagy [251]. CMA and macroautophagy
were shown to be important pathways for wild-type alpha-
syn degradation in neurons [252]. Being a soluble protein,
alpha-syn can be degraded by CMA because it contains the
CMA recognition targeting motif [253]. None of the 3 muta-
tions in familial forms of PD affect the CMA targeting motif.
Nevertheless, the wild-type protein, contrary to the mutant
forms, is readily translocated into the lysosomal lumen
whereas the mutant forms remain bound to the complex not
only blocking its degradation but also the degradation of
other substrates. Moreover, posttranslational modifications
of alpha-syn that promote its oligomerization have a similar
effect, suggesting that alpha-syn oligomers may block lyso-
somal translocation and CMA [248]. For example, in mouse
ventral medial neuron cultures, SH-SY5Y cells, and isolated
mouse lysosomes, dopamine-modified alpha-syn is not only
poorly degraded by CMA but also blocks degradation of
other substrates by this pathway [254]. While the narrow
proteasome barrel excludes the entry of oligomers/aggregates
of alpha-syn, such substrates can be degraded efficiently by
macroautophagy. The ability of alpha-syn to inhibit protea-
some activity is related to its propensity to assemble into
filaments [255]. Indeed, fibrillar forms of the protein usually
get jammed inside proteasome blocking its activity [256].
Interestingly, disruption of autophagy by RNA interference
significantly increased alpha-syn oligomer accumulation in
vitro, confirming the significance of macroautophagy in
alpha-syn clearance. In addition, rotenone-induced alpha-
syn aggregates were cleared following rapamycin stimulation
of autophagy [246]. Rapamycin inhibits the mammalian tar-
get of rapamycin (mTOR), a negative regulator of autophagy
[257]. Rapamycin has been shown to degrade all forms of
alpha-syn in a stable inducible PC12 cell model [251].
These findings support the concept that neuronal autophagy
is essential for protein homeostasis as well as for the
reduction of the potentially pathogenic alpha-syn oligomers.
Coexpression of Beclin-1, a regulator of the autophagic
pathway, was found to activate autophagy, reduce accu-
mulation of alpha-syn, and ameliorate associated neuritic
alterations in a neuronal cell line that overexpressed alpha-
syn. This neuronal cell line showed lysosomal accumulation
and alterations in autophagy [258].
Ageing seems to affect mitochondria particularly. Mito-
chondria undergo the most dramatic age-related changes,
such as structural deterioration like swelling and loss of
cristae, sometimes complete destruction of the inner mem-
brane, decreased respiration, and low ATP production [137].
Often they are extremely enlarged and are called “giant”
mitochondria [259, 260]. Nonfunctional mitochondria are
important sources of ROS which contribute to the accu-
mulation of damaged and nonfunctional components in
the cells which is characteristic of ageing. In addition,
because of mitochondrial ROS generation, protein damage
occurs and mtDNAmutations accumulate at an accelerating
rate. Subsequently, this leads to the synthesis of abnor-
mal mitochondrial proteins exacerbating mitochondrial
dysfunction.
During recent years, accumulating evidence has been
gathered showing that mitochondria also may be subject
to selective degradation through mitophagy. Mitophagy is
important to the elimination of dysfunctional mitochondria
and mutated mtDNA since DNA repair in mitochondria
is much less robust than in the nucleus [261]. There are
many reports showing mitochondria within autophago-
somes [262–264]. It was then proposed that damaged
mitochondria are captured and digested by the lysosome.
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Figure 1: The mitochondrial cascade hypothesis for PD states that the inherited electron transport chain gene combinations determine basal
ETC efficiency and ROS production. This defines the rate at which acquired mtDNA alterations occur determining when mitochondrial
impairment reaches a threshold that activates the pathologic characteristics of PD. Mitochondrial impairment in PD is characterized
by a complex I defect, which leads to ATP depletion and NAD+/NADH ratio imbalance promoting microtubule disruption. Moreover,
mitochondrial membrane potential is lost and calcium homeostasis is deregulated, which leads to calpains activation. In addition, the levels
of mitochondrial ROS are significantly increased triggering oxidative stress. These all prompt alpha-syn oligomerization either by interaction
with free tubulin, calpains or by oxidation. The end result is alpha-syn oligomerization and accumulation of alpha-syn oligomers as well as
of disrupted organelles culminating in neurodegeneration.
The evidence for mitophagy comes from a work in yeast
that identifies a specific protein in the mitochondrial outer
membrane Uth1p, whose presence is necessary for mito-
chondrial macroautophagy. Degradation of mitochondrial
proteins did not occur in mutant strains carrying null muta-
tions of Uth1p [265]. Additionally, autophagic sequestration
of mitochondria is further supported by the observation
that protein markers of mtDNA are lost together with
protein markers of mitochondrial inner membrane such as
cytochrome oxidase subunit IV and subunit I. Parkin and
PINK-1 PD-related proteins were recently associated to
mitophagy. Chu and coworkers showed that MPP+ induced
autophagy andmitochondrial degradation that was inhibited
by siRNA knockdown of autophagy proteins Atg5, Atg7, and
Atg8 [266]. Moreover, it was shown that Parkin promotes
autophagy of damaged mitochondria and further supports
that PD pathogenesis implicates a failure in the elimi-
nation of dysfunctional mitochondria [154]. Furthermore,
stable knockdown of pink-1 induced oxidative stress and
mitochondrial fragmentation in SH-SY5Y cells through
autophagic and fission/fusion machineries [156]. A report
from 2010 demonstrated a new interaction between PINK-
1 and Beclin1, a key proautophagic protein. PINK-1 signif-
icantly enhanced basal and starvation-induced autophagy,
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which was reduced by knocking down beclin1 expression
[267]. Another report provided data linking PINK-1 and
parkin to the selective autophagy of mitochondria [268].
In PD, autophagy is of extreme importance once it allows
cells to rid themselves of damaged and superfluous mito-
chondria, as well as other organelles and most interestingly
of protein aggregates accumulation.
6. Concluding Remarks
PD affects 1% of the population at age of 65 and up to
5% of the population by age 85 [269] and is the second
most common neurodegenerative disorder after AD. Efforts
have been made in order to elucidate PD trigger mechanisms
within the cell and further consequences. Compelling data
suggests that mtDNA alterations may lead to a massive
mitochondrial impairment and thus triggering the death
of dopaminergic neurons. When mitochondrial dysfunction
reaches a critical threshold inside the cell it rouses ATP
depletion, oxidative stress, and calcium homeostasis dereg-
ulation that in turn induces microtubule disruption, alpha-
syn oxidation, and calpains activation. In addition, the fusion
and fission machinery is impaired as well as autophagy
leading to the accumulation of alpha-syn oligomers and
disrupted organelles (Figure 1). This accumulation creates a
positive feedback loop causing the pathology and ultimately
the death of dopaminergic neurons. Further studies need to
be performed to understand how and when mitochondrial
dysfunction starts and why it affects a specific group of
neurons. The therapeutic challenge might start acting at an
mtDNA level or at a microtubule level improving the degra-
dation of alpha-syn oligomers and disrupted organelles.
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